U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284043) titled 'A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism' on Nov. 23.
Brief Summary: MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of [14C] MT1013.
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Hemodialysis Subjects With Secondary Hyperparathyroidism
Intervention:
DRUG: [14C] MT1013/MT1013 Injection
[14C] MT1013/MT1013 Injection
Recruitment Status: RECRUITING
Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Published by HT Digital Cont...